Evidence map›Paper›PMID 41604043›Full record

ArticleBreast cancer research and treatment2026

Breast cancer risk level and prediction of tumor aggressiveness in the Athena Breast Health Network.

Katherine Leggat-Barr, Tomiyuri Lewis, Jeffrey A Tice, Elene Tsopurashvili, Rosalyn Sayaman, Paige Warner, Kathy Malvin, Leah Sabacan, Alexandra Perry-Solomon, Sarah Theiner and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Katherine Leggat-Barr *University of California, San Francisco, San Francisco, CA, 94115, USA.
Tomiyuri Lewis *University of California, San Francisco, San Francisco, CA, 94115, USA.
Jeffrey A TiceUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Elene TsopurashviliUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Rosalyn SayamanUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Paige WarnerUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Kathy MalvinUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Leah SabacanUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Alexandra Perry-SolomonUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Sarah TheinerUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Irene AcerbiUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Ann GriffinUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Joseph McGuireUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Vivian LeeUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Alexander D BorowskyUniversity of California, Davis, Sacramento, CA, 95817, USA.
Wisdom Study and Athena Breast Health Network Investigators and Advocate Partners
Martin EklundKarolinska Institute, Stockholm, Sweden.
Celia KaplanUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Robert A HiattUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Allison Stover FiscaliniUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Karla KerlikowskeUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Yiwey ShiehWeill Cornell Medicine, New York, NY, 10065, USA.
Laura EssermanUniversity of California, San Francisco, San Francisco, CA, 94115, USA.
Laura Van't VeerUniversity of California, San Francisco, San Francisco, CA, 94115, USA. Laura.vantveer@ucsf.edu.

Funding

Risk-based Imaging Strategies to Improve Breast Cancer Surveillance OutcomesP01CA154292 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Diana L Miglioretti · 2011 to 2026
$52.9M
A systems biology approach to elucidate the biology of immune-associated outcomes in breast cancerK01CA279498 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Rosalyn Wong Sayaman · 2023 to 2026
$696k
NCI NIH HHS K01 CA279498NCI NIH HHS P01 CA154292
6 · The paper itself

Abstract

purposeDetermine the association between the Breast Cancer Surveillance Consortium v2 model (BCSC) risk score and advanced and non-advanced invasive breast cancer (IBC).

methodsWe estimated BCSC 5-year invasive breast cancer risk for 11,915 participants in a prospective screening cohort with median follow-up of 6.9 years prior to breast cancer diagnosis. Individuals in the top 25% by age of BCSC risk standard were considered high-risk, those in the bottom 75% low-risk. We obtained cancer outcomes, including American Joint Committee on Cancer (AJCC) prognostic pathologic stage, from the San Francisco Mammography Registry and an institutional cancer registry. We examined the associations of BCSC risk scores with advanced (≥ AJCC prognostic stage II) and non-advanced (AJCC prognostic stage I) IBC using Fisher's exact test and logistic regression.

resultsOf 11,915 participants, 4,005 (34%) were high-risk. There were 254 incident IBC cases, of which 40 (16%) were advanced and 214 (84%) were non-advanced. The median 5-year BCSC risk score for women with and without IBC was 1.83% and 1.45%, respectively (p < 0.001). High BCSC risk among women diagnosed with breast cancer was associated with non-advanced cancer (OR = 2.25, 95% CI = 1.71-2.95, p < 0.0001), but not with advanced cancer (OR = 1.20, 95% CI = 0.63-2.29, p = 0.57) compared to women not diagnosed with breast cancer.

conclusionHigh BCSC risk scores were associated with high rates of non-advanced IBC. As non-advanced cancers are more likely to be hormone receptor-positive, BCSC may optimally identify candidates for endocrine risk reduction.

Indexed as

Breast NeoplasmsAdultAgedEarly Detection of CancerFemaleHumansMammographyMiddle AgedNeoplasm InvasivenessNeoplasm StagingPrognosisProspective StudiesRegistriesRisk AssessmentRisk FactorsBreast screeningCohort studyPreventionRisk asssessment

Identifiers

PMID41604043
PMCPMC12852213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.